Pembrolizumab-induced acquired perforating dermatosis

Yaron Gu; Dinuke de Silva; Christopher J.A. Henderson; Deshan F. Sebaratnam

doi:10.1002/jvc2.462

Pembrolizumab-induced acquired perforating dermatosis

Yaron Gu, Dinuke de Silva, Christopher J.A. Henderson, Deshan F. Sebaratnam

Research output: Contribution to journal › Article › peer-review

19 Downloads (Pure)

Abstract

Immune checkpoint inhibitors such as the programmed cell death-1 (PD-1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid-organ malignancies. However, cutaneous adverse effects with PD-1 inhibitor therapy are common and include lichenoid reactions, eczema, vitiligo and bullous dermatoses. Perforating dermatosis is a rare condition characterised by the extrusion of degenerate materials from the upper dermis through the epidermis and has rarely been reported in association with PD-1 inhibitor therapy. Herein, we report the first case to our knowledge of acquired perforating dermatosis following treatment with pembrolizumab.

Original language	English
Pages (from-to)	1611-1614
Number of pages	4
Journal	JEADV Clinical Practice
Volume	3
Issue number	5
DOIs	https://doi.org/10.1002/jvc2.462
Publication status	Published - Dec 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Keywords

drug eruptions
immune checkpoint inhibitors
PD-1 inhibitors
programmed cell death protein 1 inhibitor

Access to Document

10.1002/jvc2.462Licence: CC BY-NC-ND

Full textFinal published version, 4.26 MBLicence: CC BY-NC-ND

Cite this

@article{4d7e71deab924e10be9c3a73eb0d0c7b,

title = "Pembrolizumab-induced acquired perforating dermatosis",

abstract = "Immune checkpoint inhibitors such as the programmed cell death-1 (PD-1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid-organ malignancies. However, cutaneous adverse effects with PD-1 inhibitor therapy are common and include lichenoid reactions, eczema, vitiligo and bullous dermatoses. Perforating dermatosis is a rare condition characterised by the extrusion of degenerate materials from the upper dermis through the epidermis and has rarely been reported in association with PD-1 inhibitor therapy. Herein, we report the first case to our knowledge of acquired perforating dermatosis following treatment with pembrolizumab.",

keywords = "drug eruptions, immune checkpoint inhibitors, PD-1 inhibitors, programmed cell death protein 1 inhibitor",

author = "Yaron Gu and {de Silva}, Dinuke and Henderson, {Christopher J.A.} and Sebaratnam, {Deshan F.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2024",

month = dec,

doi = "10.1002/jvc2.462",

language = "English",

volume = "3",

pages = "1611--1614",

journal = "JEADV Clinical Practice",

issn = "2768-6566",

publisher = "John Wiley and Sons Inc",

number = "5",

}

TY - JOUR

T1 - Pembrolizumab-induced acquired perforating dermatosis

AU - Gu, Yaron

AU - de Silva, Dinuke

AU - Henderson, Christopher J.A.

AU - Sebaratnam, Deshan F.

PY - 2024/12

Y1 - 2024/12

N2 - Immune checkpoint inhibitors such as the programmed cell death-1 (PD-1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid-organ malignancies. However, cutaneous adverse effects with PD-1 inhibitor therapy are common and include lichenoid reactions, eczema, vitiligo and bullous dermatoses. Perforating dermatosis is a rare condition characterised by the extrusion of degenerate materials from the upper dermis through the epidermis and has rarely been reported in association with PD-1 inhibitor therapy. Herein, we report the first case to our knowledge of acquired perforating dermatosis following treatment with pembrolizumab.

AB - Immune checkpoint inhibitors such as the programmed cell death-1 (PD-1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid-organ malignancies. However, cutaneous adverse effects with PD-1 inhibitor therapy are common and include lichenoid reactions, eczema, vitiligo and bullous dermatoses. Perforating dermatosis is a rare condition characterised by the extrusion of degenerate materials from the upper dermis through the epidermis and has rarely been reported in association with PD-1 inhibitor therapy. Herein, we report the first case to our knowledge of acquired perforating dermatosis following treatment with pembrolizumab.

KW - drug eruptions

KW - immune checkpoint inhibitors

KW - PD-1 inhibitors

KW - programmed cell death protein 1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85193708657&partnerID=8YFLogxK

U2 - 10.1002/jvc2.462

DO - 10.1002/jvc2.462

M3 - Article

AN - SCOPUS:85193708657

SN - 2768-6566

VL - 3

SP - 1611

EP - 1614

JO - JEADV Clinical Practice

JF - JEADV Clinical Practice

IS - 5

ER -

Pembrolizumab-induced acquired perforating dermatosis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this